Company Overview of Histogen, Inc.
Histogen, Inc. researches, develops, manufactures, and sells regenerative medicine. It offers ExCeltrix, an insoluble extracellular matrix for therapeutic applications, which include use of dermal filler for soft tissue augmentation, bone filler for bone stimulation and critical defect repair, tissue regeneration patches for surgical applications, and coatings for devices in the areas of cardiovascular, orthopedics, and urological repair. The company also provides cell conditioned media; and hair stimulating complex, a liquid formula created by the culturing of newborn cells in a simulated embryonic environment of suspension and very low oxygen, and then harvesting the naturally secreted gro...
10655 Sorrento Valley Road
San Diego, CA 92121
Founded in 2007
Key Executives for Histogen, Inc.
Founder, Chairman and Chief Executive Officer
President and Chief Financial Officer
Director of Corporate Communications
Director of Clinical Affairs
Compensation as of Fiscal Year 2014.
Histogen, Inc. Key Developments
Histogen, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 18 14
Histogen, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Histogen, Inc. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 10:15 AM
Oct 4 14
Histogen, Inc. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 10:15 AM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States.
Histogen Inc. Partners with Southern California Medical Device Group Wylde, LLC to Create Histogen Oncology
Jul 12 14
Histogen Inc. has partnered with Wylde, LLC to create Histogen Oncology. This joint venture will focus on the development of unique cell-derived materials for cancer applications. Under this joint venture, Histogen Oncology has acquired exclusive rights to Histogen's human multipotent cell conditioned media (CCM) and extracellular matrix (ECM) materials, as well as their derivatives, for oncology applications throughout North America. Histogen Oncology's initial clinical focus is pancreatic cancer, a highly treatment-resistant cancer in which a sub-fraction of the CCM has shown substantial preclinical promise. There are so many patients out there who are not candidates for existing therapies due to the toxic nature of available drugs. This is particularly true in pancreatic cancer, where 80% of people diagnosed already have stage four disease. In post-resection nude mouse models, intravenous treatment with the CCM sub-fraction resulted in prolonged survival by more than three fold in a majority of treated animals. In non-resection models, more than 50% of treated mice lived twice as long as the control. These results point to a potentially significant outcome for pancreatic cancer patients, and Histogen Oncology intends to progress the material toward a Phase I clinicaltrial for no-option pancreatic cancer patients in the coming 18 months. Research on the mechanism responsible for cancer cell inhibition by the CCM shows the upregulation of Caspase 9 and cleaved Caspase 3, which causes cancer cells to enter apoptosis, or programmed cell death. Histogen Oncology will be supported by Histogen's research group and funded by Wylde, LLC. made up of experts from the surgery and medical device industries. The creation of this joint venture allows for dedicated development of the CCM sub-fraction as a cancer treatment, as Histogen continues to allocate resources to the company's revenue-generating aesthetic and promising therapeutic programs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|